Back to search results

Computerized Cognitive Training for Acquired Brain Injury

This study is testing an intensive computerized cognitive training program called the ABI Wellness Platform, specifically using the Symbol Relations module. It's for people aged 25 to 65 who have experienced an acquired brain injury (ABI) at least 12 months ago and are experiencing difficulties with attention and executive functioning, or have a diagnosis of mild cognitive disorder or mild neurocognitive disorder. The study aims to understand what factors help improve thinking skills after this training. We will measure changes in cognitive test scores and levels of BDNF (a protein important for brain health) in your blood and saliva after 6 months. The current status of this study is unclear.

Study design
This study plans to enroll 30 participants. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
You would log into the ABI Wellness Platform five days a week for 45 to 60 minutes. Every other week, you would meet with a training facilitator via Zoom to discuss your progress.
Compensation
Not stated in the trial record.
Follow-up
Your cognitive outcomes and BDNF levels will be measured at 6 months after starting the training.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06130735

Impact of Intensive Computerized Cognitive Training

Active, Not Recruiting
NAAges 25–65InterventionalTreatment
Brigham and Women's Hospital
~30 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Cognitive Computerized Training

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in cognitive outcome measures
Measured over 6 months
+1 more outcome measured

Conditions

Acquired Brain Injury
Mild Cognitive Impairment
Mild Neurocognitive Disorder

Explore related trials

Brain InjuryMild cognitive disorder

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Kim C Willment, PhD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
  • Kirk R Daffner, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient of the Mass General Brigham Health System with primary attention and executive functioning difficulties and/or a diagnosis of mild cognitive disorder or mild neurocognitive disorder (non-amnestic profile), due to an acquired brain injury (ABI) sustained at least 12 months prior to study contact.
Ages 25-65 years old
Proficiency in English
Willing and able to complete all study-related activities for 12 months, including travel to Brigham and Women's Hospital (Boston) for four in-person assessment visits and two serum and saliva sample collections.
Access to a computer with webcam and stable internet.
A reliable study informant who can complete one questionnaire about participant's cognition/daily functioning, at four time points.

Exclusion

History of alcohol or substance abuse, or dependence, within the past 2 years, as per DSM-5 criteria.
High likelihood of an underlying progressive neurodegenerative disorder.
Evidence of moderate to severe cognitive disorder, based on a score of 21 or less on the Mini-Mental Status Examination (MMSE) (Tombaugh \& McIntyre, 1992).
Patient Health Questionnaire (PHQ)-9 (Kroenke et al., 2010) Score ≥ 19, unless deemed by treating provider not to have active depression (e.g., adjustment disorder, grief reaction).
Active psychotic symptoms.
Severe sensory losses such that participants would unlikely be able to participate in the study training, even with substantial accommodations (self-report of extreme difficulty reading ordinary newspaper print or a performance-tested corrected vision test score of worse than 20/30).
Communication difficulties that prevent the participant from effectively participating in this highly interactive study protocol (based on interviewer's rating of a person's ability to be understood and to understand others).
Current participation in a pharmacological, or other interventional research trial.
Life expectancy of \< 2 years.

What this trial measures

  • Changes in cognitive outcome measures6 months

    We will use age-corrected standard scores of the NIH toolbox Total Cognitive Composite, Fluid Intelligence Composite, and individual scores on RAVLT, Verbal Fluency, and Trailmaking Task as cognitive outcome measures.

  • Changes in BDNF Levels in blood and saliva6 months

    Using FUJIFILM high sensitivity ELISA kits and commercially available ELISA kits.